Prediction of ECT treatment response and reduction of Cognitive Side-effects using EEG and Rivastigmine
- Conditions
- Cognitieve stoornissenDepression10027946
- Registration Number
- NL-OMON54344
- Lead Sponsor
- niversitair Medisch Centrum Groningen
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- Not specified
- Target Recruitment
- 100
- Ageover 18 years
- Clinical indication for ECT (as indicated by the treating
physician/psychiatrist)
- Depressive disorder (as assessed by the treating psychiatrist)
- Dutch as first language
- Currently using rivastigmine, galantamine, donezepil (all cholinesterase
inhibitors for mild to moderate Alzheimer*s Disease).
- Pregnancy and/or lactation/breast feeding
- Suspicion of neurodegenerative disorders (as diagnosed earlier)
- Contraindications for ECT (recent myocardinfarct, recent cerebrovasculair
accident, recent intracranial surgery, pheochromocytoma and instable angina
pectoris)
- Contraindications for rivastigmine (bradycardia or atrioventricular (AV)
conduction disorders (first degree AV-block excluded))
- Patients who have had an allergic reaction to rivastigmine
- Cognitive disorder not explained by the depressive episode
- If receiving outpatient ECT treatment, having no person available to
apply the rivastigmine/non-active patch
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method